Association of Clinical Markers With Disease Progression in Patients With Vitiligo From China | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Ezzedine  K, Eleftheriadou  V, Whitton  M, van Geel  N.  Vitiligo.  Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-7PubMedGoogle ScholarCrossref
Picardo  M, Dell’Anna  ML, Ezzedine  K,  et al.  Vitiligo.  Nat Rev Dis Primers. 2015;1:15011. doi:10.1038/nrdp.2015.11PubMedGoogle ScholarCrossref
Harris  JE, Harris  TH, Weninger  W, Wherry  EJ, Hunter  CA, Turka  LA.  A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin.  J Invest Dermatol. 2012;132(7):1869-1876. doi:10.1038/jid.2011.463PubMedGoogle ScholarCrossref
Rashighi  M, Agarwal  P, Richmond  JM,  et al.  CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.  Sci Transl Med. 2014;6(223):223ra23. doi:10.1126/scitranslmed.3007811PubMedGoogle Scholar
Maouia  A, Sormani  L, Youssef  M, Helal  AN, Kassab  A, Passeron  T.  Differential expression of CXCL9, CXCL10, and IFN-γ in vitiligo and alopecia areata patients.  Pigment Cell Melanoma Res. 2017;30(2):259-261. doi:10.1111/pcmr.12559PubMedGoogle ScholarCrossref
Frisoli  ML, Harris  JE.  Vitiligo: mechanistic insights lead to novel treatments.  J Allergy Clin Immunol. 2017;140(3):654-662. doi:10.1016/j.jaci.2017.07.011PubMedGoogle ScholarCrossref
Speeckaert  R, Speeckaert  M, De Schepper  S, van Geel  N.  Biomarkers of disease activity in vitiligo: a systematic review.  Autoimmun Rev. 2017;16(9):937-945. doi:10.1016/j.autrev.2017.07.005PubMedGoogle ScholarCrossref
Rodrigues  M, Ezzedine  K, Hamzavi  I, Pandya  AG, Harris  JE; Vitiligo Working Group.  New discoveries in the pathogenesis and classification of vitiligo.  J Am Acad Dermatol. 2017;77(1):1-13. doi:10.1016/j.jaad.2016.10.048PubMedGoogle ScholarCrossref
Komen  L, da Graça  V, Wolkerstorfer  A, de Rie  MA, Terwee  CB, van der Veen  JP.  Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo.  Br J Dermatol. 2015;172(2):437-443. doi:10.1111/bjd.13432PubMedGoogle ScholarCrossref
Strassner  JP, Rashighi  M, Ahmed Refat  M, Richmond  JM, Harris  JE.  Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity.  J Am Acad Dermatol. 2017;76(5):847-855.e5. doi:10.1016/j.jaad.2016.12.021PubMedGoogle ScholarCrossref
Naldi  L, Sassi  F.  Vitiligo.  N Engl J Med. 2009;360(17):1788. doi:10.1056/NEJMc090205PubMedGoogle ScholarCrossref
Aboul-Fettouh  N, Hinojosa  J, Tovar-Garza  A, Pandya  AG.  The majority of patients presenting with vitiligo have a clinical sign of activity.  J Am Acad Dermatol. 2017;77(4):774-775. doi:10.1016/j.jaad.2017.05.027PubMedGoogle ScholarCrossref
Wang  XX, Wang  QQ, Wu  JQ,  et al.  Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo.  Br J Dermatol. 2016;174(6):1318-1326. doi:10.1111/bjd.14416PubMedGoogle ScholarCrossref
Goh  BK, Pandya  AG.  Presentations, signs of activity, and differential diagnosis of vitiligo.  Dermatol Clin. 2017;35(2):135-144. doi:10.1016/j.det.2016.11.004PubMedGoogle ScholarCrossref
Hann  SK, Kim  YS, Yoo  JH, Chun  YS.  Clinical and histopathologic characteristics of trichrome vitiligo.  J Am Acad Dermatol. 2000;42(4):589-596. doi:10.1016/S0190-9622(00)90170-1PubMedGoogle ScholarCrossref
Nicolaidou  E, Antoniou  C, Stratigos  AJ, Stefanaki  C, Katsambas  AD.  Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy.  J Am Acad Dermatol. 2007;56(2):274-278. doi:10.1016/j.jaad.2006.09.004PubMedGoogle ScholarCrossref
Cavalié  M, Ezzedine  K, Fontas  E,  et al.  Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study.  J Invest Dermatol. 2015;135(4):970-974. doi:10.1038/jid.2014.527PubMedGoogle ScholarCrossref
Richmond  JM, Strassner  JP, Zapata  L  Jr,  et al.  Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo.  Sci Transl Med. 2018;10(450):eaam7710. doi:10.1126/scitranslmed.aam7710PubMedGoogle Scholar
Riding  RL, Harris  JE.  The role of memory CD8+ T cells in vitiligo.  J Immunol. 2019;203(1):11-19. doi:10.4049/jimmunol.1900027PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    January 22, 2020

    Association of Clinical Markers With Disease Progression in Patients With Vitiligo From China

    Author Affiliations
    • 1Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
    JAMA Dermatol. 2020;156(3):288-295. doi:10.1001/jamadermatol.2019.4483
    Key Points

    Question  Can the clinical markers of vitiligo be used to assess disease progression, severity, and patient prognosis?

    Findings  In this cohort study of 458 patients with vitiligo from China, among 425 patients who completed 12-month follow-up, 224 (52.7%) did not have any clinical marker and 201 (47.3%) had at least 1 clinical marker at the first visit. The proportion of patients in the active stage was significantly higher in the cohort with clinical markers compared with the cohort without any marker at the baseline examination and at 3-month follow-up; presence of clinical markers was also associated with disease progression at 1- and 3-month follow-up

    Meaning  The findings suggest that clinical markers, including trichrome sign, confetti-like depigmentation, and Koebner phenomenon, are associated with vitiligo progression and prognosis and that patients with multiple clinical markers may require more intensive treatment.


    Importance  It is necessary to determine whether established clinical markers of vitiligo are associated with disease progression, severity, and patient prognosis.

    Objective  To evaluate the utility of trichrome sign, confetti-like depigmentation, and Koebner phenomenon in assessing disease progression, severity, and prognosis in patients with vitiligo.

    Design, Setting, and Participants  In this prospective cohort study, 425 patients with vitiligo were recruited from the outpatient department of Huashan Hospital, Fudan University in Shanghai, China, from September 1, 2016, to May 13, 2019.

    Main Outcomes and Measures  Disease progression, severity, and prognosis during a 12-month period. The active stage of vitiligo was defined as Vitiligo European Task Force spreading score of at least 1 or more lesions appearing as hypomelanotic with poorly defined borders using a Wood light. Progression was assessed using the Vitiligo Area Scoring Index (VASI) and serum CXCL10 level measurement.

    Results  Of the 458 enrolled patients, 425 (235 female [55.3%]; mean [SD] age, 30.9 [10.2] years) completed the 12-month follow-up. Of the 425 patients (224 with no clinical marker and 201 with at least 1 clinical marker) included in this analysis, the proportion in the active stage of the disease was significantly higher in the cohort with at least 1 clinical marker compared with the cohort without any clinical marker at the first visit (196 of 201 [97.5%] vs 159 of 224 [71.0%]; P < .001) and at 3-month follow up (91 of 201 [45.3%] vs 52 of 224 [23.2%]; P < .001). The proportion of patients with rapid disease progression was also higher in the group with at least 1 clinical marker at 1-month follow-up (142 of 201 [70.6%] vs 60 of 224 [26.8%]; P < .001) and 3-month follow-up (63 of 201 [31.3%] vs 9 of 224 [4.0%]; P < .001). The improvement in VASI score (SD) was significantly smaller among patients with at least 1 clinical marker compared with those without any clinical marker at 6 months (mean [SD], 0.14 [0.12] vs 0.23 [0.21]; P = .02), at 9 months (mean [SD], 0.29 [0.19] vs 0.44 [0.25]; P = .03), and at 12 months (mean [SD], 0.47 [0.21] vs 0.63 [0.23]; P = .03).

    Conclusions and Relevance  The presence of a clinical marker in patients with vitiligo may be associated with worse prognosis and rapid disease progression. Patients with multiple clinical markers may require more intensive treatment.